General MedicationsINTRAVENOUSGeneric
VPRIV
VELAGLUCERASE ALFA
Standard Dose
200 UNITS/VIAL
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Discontinued
Summary
Approval overview VPRIV is listed in Drugs@FDA under application 022575 (BLA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient VELAGLUCERASE ALFA Form and strength POWDER;INTRAVENOUS - 200 UNITS/VIAL Sponsor SHIRE HUMAN GENETIC Submission history Latest submission status date: 2024-07-10 00:00:00.
Structured Monograph
Clinical summary
Approval overview VPRIV is listed in Drugs@FDA under application 022575 (BLA). Review priority: STANDARD Marketing status: Discontinued Active ingredient VELAGLUCERASE ALFA Form and strength POWDER;INTRAVENOUS - 200 UNITS/VIAL Sponsor SHIRE HUMAN GENETIC Submission history Latest submission status date: 2024-07-10 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.